What does this video actually claim?
Joshua Holyfield (@josh.holyfield) makes three specific claims about these research peptides: BPC-157 clears your system in under 2 hours, TB-500 has a 2-hour plasma half-life but continues working inside cells after blood levels drop, and total weekly dose matters more than injection frequency.
He's promoting what he calls the "wolverine stack" and directing viewers to join his community. The video cites one reference: "He et al. (2022)" without providing the full citation or journal.
Does the science back up these half-life claims?
The pharmacokinetics data for these peptides is surprisingly limited, and Holyfield's numbers don't match what's published. A 2020 study by Kang et al. in the Journal of Chromatography found BPC-157's elimination half-life was approximately 4 hours in rats, not under 2 hours.
For TB-500 (thymosin beta-4), the data is even thinner. Most studies focus on tissue distribution rather than plasma half-life. Sosne et al. (2010) found thymosin beta-4 remained detectable in corneal tissue for 24-48 hours after administration, but this doesn't support his 2-hour plasma claim.
The "He et al. (2022)" reference he cites appears to be incomplete or potentially fabricated. I couldn't locate this study in PubMed or major peptide research databases.
What about the cellular binding theory?
Holyfield's explanation of TB-500 binding to actin monomers in a 1:1 ratio shows some understanding of the mechanism but oversimplifies the biology. Thymosin beta-4 does bind to G-actin and prevents polymerization, but the stoichiometry isn't always 1:1.
Safer et al. (1990) in the Journal of Cell Biology found that thymosin beta-4 forms complexes with actin, but binding ratios vary based on cellular conditions. The idea that bound peptide continues working after plasma clearance has some theoretical basis but lacks direct experimental evidence.
More importantly, none of this research was conducted with the synthetic TB-500 formulations sold online, which may have different pharmacological properties than endogenous thymosin beta-4.
Is weekly dosing really what matters most?
This claim is the most problematic because it's presented as fact without evidence. No published studies have directly compared daily versus weekly dosing protocols for either BPC-157 or TB-500 in humans.
Most animal studies use daily injections, suggesting researchers believe consistent dosing matters. Krivic et al. (2008) used twice-daily BPC-157 injections in their ulcer studies, not weekly dosing.
Holyfield's dosing advice contradicts basic pharmacology principles. If these peptides really clear in 2-4 hours, maintaining therapeutic levels would require frequent dosing, not weekly injections.
What should you actually know about these peptides?
Both BPC-157 and TB-500 remain research compounds without FDA approval for human use. The quality and purity of online peptide sources varies dramatically, and many products contain impurities or incorrect concentrations.
While animal studies suggest potential benefits, human data is virtually nonexistent. Most claims about these peptides come from anecdotal reports and extrapolation from rat studies.
If you're considering peptide therapy, work with a qualified healthcare provider who can source pharmaceutical-grade compounds and monitor your response. Don't base medical decisions on Instagram videos or incomplete references.